Objective Fibromyalgia (FM) frequently co-occurs with SLE, but its independent contribution to musculoskeletal risk is ...

Objectives To determine the prevalence of cerebral atrophy in a multi-ethnic systemic lupus erythematosus (SLE) cohort and to ...

Objective To apply large language models (LLMs) to Reddit posts referencing SLE to identify patient-expressed unmet medical ...

Objectives Low disease activity (Lupus Low Disease Activity State [LLDAS]) and remission (Definition of Remission in SLE [DORIS]) are recommended treatment targets associated with reduced organ damage ...

Background Litifilimab is a humanized IgG1 monoclonal antibody targeting BDCA2, a receptor predominantly expressed on plasmacytoid dendritic cells (pDCs). In Part A of the Phase 2 LILAC study ...

Objective Complement plays a major role in SLE. Complement participation has been linked to disease activity and damage. Our objective was to estimate the association of complement behaviour with ...

Fumaric acid esters in cutaneous lupus erythematosus Fumaric acid esters (FAEs), established immunomodulatory agents in the treatment of psoriasis and multiple sclerosis, have been investigated for ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are ...

Objective To evaluate safety and mechanism of action of mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with moderate to severe systemic lupus erythematosus (SLE). Methods A phase ...

Objectives A few clinical trials have been performed studying Bruton’s tyrosine kinase (BTK) inhibitors in patients with systemic lupus erythematous (SLE). We evaluate the literature and evidence to ...

Background The high heterogeneity in systemic lupus erythematosus (SLE) implies that differential treatment may be required for different patient strata, hence there is an increased need of accurate ...

Objective To investigate changes in peripheral B cells, B-cell subsets and biomarkers in NOBILITY. Methods In the randomized Phase II NOBILITY trial (NCT02550652), patients with lupus nephritis ...